$2.09
0.031.46%
Last update: Nov 10, 5:22 PM
Genprex Inc
GNPXNASDAQ
Genprex fell 97.6% from $88.00 to $2.09, behind the S&P 500's +10.0%. Its worst day was Jul 16 (−25.9%), and its low came Oct 23 at $1.81.
Nov 10, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-110.00 was reported on $0.00 revenue.
−8.8% · S&P 500 −0.9%
Genprex shares rose 19.6%, while the S&P 500 fell 0.5%.
+19.6% · S&P 500 −0.5%
Story events cover the past 12 months · Times ET
Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.’sTecentriq®
+27.5%, the year's best day · S&P 500 −1.0%
EPS of $123.20 was reported on $0.00 revenue.
+2.3% · S&P 500 +2.9%
EPS of $-14.08 was reported on $0.00 revenue.
+1.2% · S&P 500 +0.8%
Genprex shares fell 24.0%, while the S&P 500 rose 1.8%.
−24.0% · S&P 500 +1.8%
Genprex shares fell 25.9%, while the S&P 500 fell 0.5%.
−25.9%, the year's worst day · S&P 500 −0.5%
Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.
−20.7% · S&P 500 +1.4%
EPS of $-9.40 was reported on $0.00 revenue.
+3.6% · S&P 500 −0.5%
Genprex closed at its lowest level of the year, 97.9% below where the year started.
−8.6% · S&P 500 −0.5%
Where it ended: a close of $2.09 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 24, 2026.
Nothing in the past 12 months.
All GNPX analyst actionsNothing in the past 12 months.
All GNPX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for GNPX and SPY from Benzinga historical bars. Not investment advice.
